Latest Breaking News On - Galera therapeutics inc - Page 8 : comparemela.com

3 Biotech Stocks Poised to Beat Q2 Earnings Estimates – 24/7 Wall St.

These three stocks are expected to deliver an earnings surprise in their upcoming quarterly results.

Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

Company received Complete Response Letter from FDA for avasopasem and intends to request Type A meeting with FDA to discuss potential next steps Cash runway extended into Q2 2024 in connection with. -Today at 07:02 am- MarketScreener

Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese

Galera shares tank after US FDA declines to approve inflammation disease drug

(Reuters) - Galera Therapeutics Inc said the U.S. health regulator declined to approve its drug to treat radiotherapy-induced severe mouth inflammatio.

Galera Gets CRL From FDA For Avasopasem Manganese, To Cut 70% Jobs; Stock Down In Premarket

Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on cancer treatment, announced Thursday that it has received a Complete Response Letter or CRL from the U.